Watson Biotech: Subsidiary received registration certificate for 13-valent pneumococcal polysaccharide conjugate vaccine in Jordan.

Watson Pharmaceuticals announced that its subsidiary Yuxi Watson Biotechnology Co., Ltd. recently received the "Drug Registration Certificate" issued by the Jordan Food and Drug Administration for the production of 13-valent pneumococcal polysaccharide conjugate vaccine. Yuxi Watson's 13-valent pneumococcal polysaccharide conjugate vaccine is mainly suitable for vaccination of infants and children aged 6 weeks to 5 years, used to prevent infectious diseases caused by the 13 serotypes of pneumococcus included in this vaccine. The vaccine was approved for sale in the domestic market in 2020.